Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer

Mengmeng Liu et al.

Expert Review of Pharmacoeconomics & Outcomes Research2026https://doi.org/10.1080/14737167.2026.2642646article
ABDC C
Weight
0.50

What the paper says

Tucatinib plus trastuzumab was cost-effective if its price was the same as lapatinib for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic CRC from the perspective of healthcare payers in China. Our exploratory result could provide a reference for clinical application of tucatinib plus trastuzumab when they are correctly interpreted.

Open paper page →

Cite this paper

https://doi.org/https://doi.org/10.1080/14737167.2026.2642646

Or copy a formatted citation

@article{mengmeng2026,
  title        = {{Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer}},
  author       = {Mengmeng Liu et al.},
  journal      = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year         = {2026},
  doi          = {https://doi.org/https://doi.org/10.1080/14737167.2026.2642646},
}

Paste directly into BibTeX, Zotero, or your reference manager.

Flag this paper

Cost-effectiveness analysis of tucatinib plus trastuzumab versus pertuzumab plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer

Flags are reviewed by the Arbiter methodology team within 5 business days.


Evidence weight

0.50

Balanced mode · F 0.40 / M 0.15 / V 0.05 / R 0.40

F · citation impact0.50 × 0.4 = 0.20
M · momentum0.50 × 0.15 = 0.07
V · venue signal0.50 × 0.05 = 0.03
R · text relevance †0.50 × 0.4 = 0.20

† Text relevance is estimated at 0.50 on the detail page — for your query’s actual relevance score, open this paper from a search result.